Ea4181- A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab And High Dose Cytarabine (Br/Cr) 2.) Bendamustine, Rituximab, High Dose Cytarabine And Acalabrutinib (Br/Cr-A), And 3.) Bendamustine, Rituximab And Acalabrutinib (Br-A) In Pat
Posted Date: Mar 11, 2020
- Investigator: Tahir Latif
- Specialties: Cancer, Lymphoma, Oncology
- Type of Study: Observational/Survey
This is a study for untreated mantle cell lymphoma patients. The primary objective of this study is to compare the CR/Peripheral blood MRD negative rate between the 3 arms of the study.
Criteria:
To Be Eligible: Patients Must Be Age = 18 Years And = 70 Years, Ecog 0-2, Untreated Histologically Confirmed Mantle Cell Lymphoma, No History Of Hypersensitivity To Study Drugs/Components, No Active Infections Or Medical Disorders That May Affect Treatmen
Keywords:
Lymphoma
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com